title: Radioiodine for High Risk and Radioiodine Refractory Thyroid Cancer: Current Concepts in Management.
abstract: The management of early stage differentiated thyroid cancer (DTC) with low risk of recurrence has been the subject of much interest and investigation in the recent years. Locally advanced DTC and patients with a high risk of recurrent disease however needs further investigation. This short review will look at what constitutes high risk thyroid cancer, the definition of radioiodine refractory disease, the current management and areas of debate within this clinical setting.
authors.affiliation: Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address: Kate.Newbold@icr.ac.uk.
authors.forename: K L
authors.initials: KL
authors.lastname: Newbold
authors.affiliation: Department of Medical Physics, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.
authors.forename: G
authors.initials: G
authors.lastname: Flux
authors.affiliation: Department of Clinical Oncology, Weston Park Hospital, Sheffield Teaching Hospitals Trust, Sheffield, UK.
authors.forename: J
authors.initials: J
authors.lastname: Wadsley
mesh_terms: D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D012306:Risk; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*
chemical_list: D007457:Iodine Radioisotopes
keywords: Cancer; kinase inhibitors; re-differentiation; thyroid